Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04425018 · ClinicalTrials.gov registry record · Phase 2
MARGetuximab Or Trastuzumab (MARGOT)
A Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
- 14
- Study locations
NCT04425018 is a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 174 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT04425018, a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
- DRUG Pertuzumab
- DRUG Margetuximab
Study Locations (14)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Dana-Farber Brigham Cancer Center - Foxborough - Foxborough
- Dana-Farber at Milford - Milford
- Dana-Farber at South Shore Hospital - Weymouth
Pennsylvania
- UPMC Hillman Cancer Center - Arnold Palmer at Mountain View - Greensburg
- UPMC Hillman Cancer Center - Arnold Palmer at Norwin - Irwin
- University of Pittsburgh Medical Center - Pittsburgh
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Texas
- Baylor College of Medicine Medical Center - Houston
- MD Anderson Cancer Center - Houston
New York
- Montefiore Medical Center - The Bronx
Washington
- University of Washington Fred Hutchinson Cancer Care - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04425018
The ClinicalTrials.gov registry entry for NCT04425018 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.
NCT04425018 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04425018 about?
NCT04425018 is a clinical study titled "MARGetuximab Or Trastuzumab (MARGOT)". The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzuma...
What is the current status of trial NCT04425018?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2020-07-13. Estimated completion is 2027-07-01.
What conditions does trial NCT04425018 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer.
What interventions are being tested in trial NCT04425018?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Pertuzumab (DRUG), Margetuximab (DRUG).
Who is sponsoring clinical trial NCT04425018?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04425018 being conducted?
This trial has 14 study locations across District of Columbia, Massachusetts, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Breast Cancer
All registered trials for this condition
HER2-positive Breast Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.